ArticleBritish journal of cancer2010
p53 mutation, deprivation and poor prognosis in primary breast cancer.
Article in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 60 citations in OpenAlex.
- Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival.Breast cancer research and treatment · 2026Observational
- Area deprivation index and breast cancer outcomes among patients in Western New York.Breast cancer research and treatment · 2025Article
- Genomic Analysis Reveals Racial and Age-Related Differences in the Somatic Landscape of Breast Cancer and the Association with Socioeconomic Factors.Cancer research · 2025Article
- Population-specific Mutation Patterns in Breast Tumors from African American, European American, and Kenyan Patients.Cancer research communications · 2023Article
- Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer.BMC medical genomics · 2023Article
- Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy.Communications medicine · 2023Article
- HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.EBioMedicine · 2022Article
- Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases.NPJ breast cancer · 2022Article
- TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- ∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ERThe journal of pathology. Clinical research · 2020Article
- Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients.PloS one · 2019Article
- Effects of zerumbone on proliferation and apoptosis of esophageal cancer cells and on P53 and Bcl-2 expression levels.Oncology letters · 2018Article
- Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database.Annals of surgical oncology · 2018Article
- Analysis of Tumor Biology to Advance Cancer Health Disparity Research.The American journal of pathology · 2018Review
- Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.Oncogene · 2017Article
- Association between Mutation and Expression ofCancer research and treatment · 2016Article
- Article
- Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.Medicine · 2016Article
- Integration of molecular pathology, epidemiology and social science for global precision medicine.Expert review of molecular diagnostics · 2016Review
- Adiposity is associated with p53 gene mutations in breast cancer.Breast cancer research and treatment · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe deprivation gap for breast cancer survival remains unexplained by stage at presentation, treatment, or co-morbidities. We hypothesised that p53 mutation might contribute to the impaired outcome observed in patients from deprived communities.
methodsp53 mutation status was determined using the Roche Amplichip research test in 246 women with primary breast cancer attending a single cancer centre and related to deprivation, pathology, overall, and disease-free survival.
resultsp53 mutation, identified in 64/246 (26%) of cancers, was most common in 10 out of 17 (58.8%) of the lowest (10th) deprivation decile. Those patients with p53 mutation in the 10th decile had a significantly worse disease-free survival of only 20% at 5 years (Kaplan-Meier logrank chi(2)=6.050, P=0.014) and worse overall survival of 24% at 5 years (Kaplan-Meier logrank chi(2)=6.791, P=0.009) than women of deciles 1-9 with p53 mutation (c.f. 56% and 72%, respectively) or patients in the 10th decile with wild-type p53 (no disease relapse or deaths).
conclusionp53 mutation in breast cancer is associated with socio-economic deprivation and may provide a molecular basis, with therapeutic implications, for the poorer outcome in women from deprived communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.